Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US8342033094
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG0024L5B86
SLNO
Soleno Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Soleno Therapeutics Inc
ISIN
US8342033094
TICKER
SLNO
MIC
XNAS
REUTERS
SLNO.OQ
BLOOMBERG
SLNO US
Mo., 27.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 26.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 26.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Soleno Therapeutics
US8342033094

NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit.   CLASS DEFINITION: The...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 23.04.2026       Soleno Therapeutics
US8342033094

Important Notice Regarding Alleged DCCR Safety Data MisrepresentationsNEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt notifies investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between March 26, 2025 and November 4, 2025. Find out if you qualify to...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates in...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO)....
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Soleno Therapeutics
US8342033094

From Optimism to Disillusionment: How Investor Sentiment ShiftedNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP provides context on the dramatic shift in investor sentiment surrounding Soleno Therapeutics, Inc. (NASDAQ: SLNO) and its only commercial product, VYKAT XR (diazoxide choline extended-release tablets, or DCCR), approve...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Soleno Therapeutics
US8342033094

Bernstein Liebhard LLP:Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?Did you purchase your shares between March 26, 2025 and August 4, 2025, inclusive?Did you lose money in your investment in Soleno Therapeutics, Inc.?Do you want to discuss your rights?New York, New York--(Newsfile Corp. - April 21, 2026) - Bernstein Li...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 20.04.2026       Soleno Therapeutics
US8342033094

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Soleno Therapeutics
US8342033094

NEW ORLEANS, April 17, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO), if they purchased or otherwise acquired the Comp...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Soleno Therapeutics
US8342033094

San Diego, California--(Newsfile Corp. - April 17, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the "Class Period"), have until Tuesday, May 5, 2026 to seek appointment as lead plaintiff of the S...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates in...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Soleno Therapeutics
US8342033094

BENSALEM, Pa., April 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SOLENO THERAPEUTICS, INC. (S...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-ma...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Soleno Therapeutics
US8342033094

Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO) to contact the firm. Those who purchased SLNO securities between March 26, 2025 and November 4, 2025 may be entitled to recover damages.  Find out if you...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 15, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) have opportunity to lead the securities fraud class action lawsuit....
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 15, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Soleno Therapeutics
US8342033094

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug SafetyNEW YORK, April 15, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action....
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Soleno Therapeutics
US8342033094

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basi...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 14, 2026) - Bernstein Liebhard LLP:Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?Did you purchase your shares between March 26, 2025 and August 4, 2025, inclusive?Did you lose money in your investment in Soleno Therapeutics, Inc.?Do you want to discuss your rights?Bernstein Li...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 13, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Zur Nachricht
Soleno Therapeutics
Charts & Research Termsheets Terminal
Permalink